ProKidney Confirms Phase 3 Enrollment Progress, Q2 2027 Topline Results, and FDA Alignment for Accelerated Approval
PROK has more than doubled off its 52-week low of $0.54.
Summary
ProKidney announced significant progress in its Phase 3 PROACT 1 clinical trial, confirming mid-2026 enrollment completion and Q2 2027 topline results, alongside positive FDA alignment for accelerated approval.
Key Events · Product Development and Regulatory · PROK
-
Phase 3 Enrollment On Track
The company expects to complete enrollment for the PROACT 1 accelerated approval analysis by mid-2026.
-
Pivotal Topline Results Expected
Pivotal topline results for the PROACT 1 study are anticipated in Q2 2027.
-
FDA Alignment Confirmed
The company reaffirmed FDA agreement on eGFR slope as a surrogate endpoint for accelerated approval, with a 1.5 mL/min/1.73m² effect size being an acceptable demonstration of efficacy.
-
Positive Phase 2 Data Highlighted
Phase 2 REGEN-007 study results showed a 4.6 mL/min/1.73m² improvement in eGFR slope, exceeding the FDA's acceptable threshold for efficacy.
Analysis · PROK · Life Sciences
This filing provides crucial updates on ProKidney's lead product candidate, rilparencel, including being on track to complete Phase 3 PROACT 1 enrollment by mid-2026 and anticipating pivotal topline results in Q2 2027. The company also reiterated FDA alignment on using eGFR slope as a surrogate endpoint for accelerated approval, with Phase 2 data showing a significant improvement that exceeds the FDA's acceptable efficacy demonstration. These updates offer clarity on the development timeline and regulatory path for its core asset.
At the time of this filing, PROK was trading at $1.61 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $485.8M. The 52-week trading range was $0.54 to $7.13. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.